NR3C2 and metabolic dysfunction-associated steatohepatitis: In contrast, experimental studies have shown that MR antagonism provides a hepatoprotective effect against steatosis and fibrosis in NASH, which underscores the role of MR in promoting the development and progression of MASLD (84, 85).